<?xml version="1.0" encoding="UTF-8"?>
<boxed-text id="pmed.1002882.box002" position="float" orientation="portrait">
 <sec id="sec003">
  <title>Box 1. Five questions addressed during discussions about key populations in clinical trials of TB therapeutics [
   <xref rid="pmed.1002882.ref013" ref-type="bibr">13</xref>]
  </title>
  <list list-type="order">
   <list-item>
    <p>Aside from the use of well-designed trials based on solid preclinical data conducted under the protections outlined in existing regulations, what are the biggest barriers to including key populations in clinical trials? What approaches or measures might stimulate greater inclusion of key populations in trials, including greater community engagement and awareness?</p>
   </list-item>
   <list-item>
    <p>What would make the inclusion of key populations easier for researchers?</p>
   </list-item>
   <list-item>
    <p>What special considerations need to be taken into account to include key populations into trials? Can they be included as an additional arm of study? A part of a larger patient group?</p>
   </list-item>
   <list-item>
    <p>At what phase is it most appropriate to include key populations?</p>
   </list-item>
   <list-item>
    <p>Areas where key populations are included should be prioritized based on burden. What are these priority areas, and what are the requirements for each population?</p>
   </list-item>
  </list>
 </sec>
</boxed-text>
